ThromboGenics announced data from two Phase 3 clinical trials evaluating ocriplasmin for the treatment of vitreomacular traction (VMT) and macular holes. The studies highlight that a single ...

The pivotal studies, published in the New England Journal of Medicine, showed that patients who were treated with Jetrea successfully achieved resolution of VMT and closure of macular holes as ...

Both studies met their primary endpoint and demonstrated that JETREA® successfully resolved VMT and macular holes compared to placebo. At day 28, 26.5% Jetrea-treated patients achieved resolution ...

The paper highlights that a single intravitreal injection of ocriplasmin resolved Vitreomacular Adhesion (VMA), releasing traction and closing macular holes in significantly more patients than placebo ...

The CHMP’s opinion was based on data submitted from two pivotal phase III studies which showed that Jetrea successfully resolved VMT and macular hole compared to placebo. Belgian ...

The study consisted of an online electronic survey sent to the Macula Society membership to gather data on eyes with vitreomacular traction, with or without macular hole, treated with intravitreal ...

Two DRCR.net studies evaluated the safety and efficacy of PVL for symptomatic VMT without macular hole (Protocol AG) and with macular hole (Protocol AH). Protocol AG was a randomized clinical ...